AMRI   3Q Revenues: $152.7 million (+46%) 3Q Loss: $23.4 million (loss of $4.2 billion 3Q15) YTD Revenues: $379.1 million (+37%) YTD Loss: $54.8 million (loss of $4.1 million YTD15) Comments: Contract revenue was $151.7 million in the quarter, up 50% primarily related to the acquisition of Euticals. Recurring royalty revenue in the quarter was $1.1 million, down from $3.2 million in 3Q15, reflecting a change in estimate of the second quarter royalties related to Allergan’s sa...